ClinicalTrials.gg
CompletedNCT02077192Updated Dec 11, 2023Results posted

Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

A Phase 3 interventional study of Fostamatinib Disodium in Immune Thrombocytopenic Purpura, sponsored by Rigel Pharmaceuticals. Completed at 55 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-11.

Sponsored by Rigel Pharmaceuticals · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
123
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 50 studies in Purpura, Thrombocytopenic, Idiopathic with a site in United Kingdom — 7 open to participants now, 12 under way, 8 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · United Kingdom.

Enrollment
13th of 46
123 · median 72
Started
2014
with 4 others
Phase 3
23 of 50
3 open now
Registered
11th of 50
by date
Lead sponsor
2 of 50
Rigel Pharmaceuticals

Among the 50 studies in Purpura, Thrombocytopenic, Idiopathic with a site in United Kingdom, this one is the 13th largest by enrollment of the 46 interventional ones that give a count, is one of 5 that started in 2014, is one of 23 in phase 3, and was the 11th registered.

Purpura, Thrombocytopenic, Idiopathic

505 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 160 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

7 of the 50 studies in Purpura, Thrombocytopenic, Idiopathic with a site in United Kingdom are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 104 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (47%) set no upper age limit and 43 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Purpura, Thrombocytopenic, Idiopathic with a site in United Kingdom, or all of them as a file.
02

Study summary

The primary objective of this study was to assess the long term safety of fostamatinib in subjects with persistent/chronic ITP

03

Conditions studied

  • Immune Thrombocytopenic Purpura
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completed week 24 evaluation of Study C935788-047 or Study C935788-048 or discontinued early due to lack of response.
  • Able and willing to give written

Exclusion criteria

Exclusion Criteria:

  • Discontinued participation in Study C935788-047 or Study C935788-048 for any reason other than lack of response
  • Poorly controlled hypertension during Study C935788-047 or Study C935788-048
  • Significant infection, an acute infection such as influenza, or known inflammatory process
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
123 participants (actual)

Study arms

  • Experimental
    Fostamatinib Disodium

    Fostamatinib Disodium tablet 100 mg or 150 mg by mouth twice a day

    Drug: Fostamatinib Disodium

Interventions

  • DrugFostamatinibStudies of FostamatinibFostamatinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Fostamatinib Disodium tablet 100 mg or 150 mg by mouth twice a day

    Also known as: R935788, R788, Fostamatinib

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects Who Achieved Platelet Count of at Least 50,000/µL Within 12 Weeks of Beginning Treatment up to 12 Months (Fostamatinib in 047/048 or 049):Version 1

    Percentage of subjects who achieved platelet count of at least 50,000/µL within 12 Weeks of beginning treatment up to 12 months was analyzed among all subjects who received active treatment in one of the prior studies (C788-047 or C788-048), in the current extension study (C788-049), or in both prior and current studies. Treated Population was defined as all enrolled and treated subjects.

    Time frame: Up to 12 months

  2. Percentage of Subjects Who Achieved Platelet Count of at Least 50,000/µL Within 12 Weeks of Beginning Treatment up to 12 Months (Placebo in 047/048 and Fostamatinib 049): Version 2

    A within-subject, between-study comparison of platelet counts for subjects who were previously treated with placebo in one of the prior studies (C788-047 or C788-048) was prospectively defined in the protocol (version 2). Achievement of platelet response by 12 weeks and maintenance of platelet response for 12 weeks was analyzed among subjects who had been randomized to placebo in one of the prior studies (C788-047 or C788-048). Treated Population was defined as all enrolled and treated subjects.

    Time frame: Up to 12 months

Secondary outcomes

  1. Duration of Platelet Response Based on Platelet Count and Rescue Medication

    The duration of platelet response was defined as the time from when the subject first achieved a platelet count of at least 50,000/µL, until the first of 2 visits with platelet counts \< 50,000/µL that were at least 4 weeks apart without an intervening visit with a platelet count less than equal to (\<=) 50,000/µL unrelated to rescue therapy. Duration of platelet response was analyzed using the Kaplan-Meier method. Treated Population was defined as all enrolled and treated subjects. Here, a number of subjects analyzed included all subjects evaluable for this endpoint.

    Time frame: Up to 12 months

  2. Percentage of Subjects in Whom a Reduction in the Dose of Concomitant ITP Therapy Can be Achieved While Maintaining an Adequate Platelet Count

    The percentage of subjects in whom a reduction in the dose of concomitant ITP therapy could be achieved while maintaining an adequate platelet count, the reduction event was clarified to apply only to reductions in the dose of concomitant ITP therapy occurring within a period of platelet response and the reduction event was not be prompted by an adverse event.

    Time frame: Up to 12 months

07

Results

Posted Dec 11, 2023

Participant flow

A total of 124 subjects were screened from studies C788-047/ C788-048 for this extension study. Out of which, 123 subjects were enrolled and treated with study drug.

Participant flow — Overall Study
MilestoneFostamatinib Disodium
Started123
Completed29
Not completed94

Outcome measures

PrimaryPercentage of Subjects Who Achieved Platelet Count of at Least 50,000/µL Within 12 Weeks of Beginning Treatment up to 12 Months (Fostamatinib in 047/048 or 049):Version 1

Percentage of subjects who achieved platelet count of at least 50,000/µL within 12 Weeks of beginning treatment up to 12 months was analyzed among all subjects who received active treatment in one of the prior studies (C788-047 or C788-048), in the current extension study (C788-049), or in both prior and current studies. Treated Population was defined as all enrolled and treated subjects.

Time frame:
Up to 12 months
Reported as:
Number · Percentage of Subjects
Percentage of Subjects Who Achieved Platelet Count of at Least 50,000/µL Within 12 Weeks of Beginning Treatment up to 12 Months (Fostamatinib in 047/048 or 049):Version 1
Percentage of SubjectsFostamatinib Disodium
Percentage of Subjects Who Achieved Platelet Count of at Least 50,000/µL Within 12 Weeks of Beginning Treatment up to 12 Months (Fostamatinib in 047/048 or 049):Version 115.4 (9.6 to 23.1)
PrimaryPercentage of Subjects Who Achieved Platelet Count of at Least 50,000/µL Within 12 Weeks of Beginning Treatment up to 12 Months (Placebo in 047/048 and Fostamatinib 049): Version 2

A within-subject, between-study comparison of platelet counts for subjects who were previously treated with placebo in one of the prior studies (C788-047 or C788-048) was prospectively defined in the protocol (version 2). Achievement of platelet response by 12 weeks and maintenance of platelet response for 12 weeks was analyzed among subjects who had been randomized to placebo in one of the prior studies (C788-047 or C788-048). Treated Population was defined as all enrolled and treated subjects.

Time frame:
Up to 12 months
Reported as:
Number · Percentage of Subjects
Percentage of Subjects Who Achieved Platelet Count of at Least 50,000/µL Within 12 Weeks of Beginning Treatment up to 12 Months (Placebo in 047/048 and Fostamatinib 049): Version 2
Percentage of SubjectsFostamatinib Disodium
Percentage of Subjects Who Achieved Platelet Count of at Least 50,000/µL Within 12 Weeks of Beginning Treatment up to 12 Months (Placebo in 047/048 and Fostamatinib 049): Version 22.3 (0.1 to 12.0)
SecondaryDuration of Platelet Response Based on Platelet Count and Rescue Medication

The duration of platelet response was defined as the time from when the subject first achieved a platelet count of at least 50,000/µL, until the first of 2 visits with platelet counts \< 50,000/µL that were at least 4 weeks apart without an intervening visit with a platelet count less than equal to (\<=) 50,000/µL unrelated to rescue therapy. Duration of platelet response was analyzed using the Kaplan-Meier method. Treated Population was defined as all enrolled and treated subjects. Here, a number of subjects analyzed included all subjects evaluable for this endpoint.

Time frame:
Up to 12 months
Reported as:
Median · Days
Duration of Platelet Response Based on Platelet Count and Rescue Medication
DaysFostamatinib Disodium
Duration of Platelet Response Based on Platelet Count and Rescue Medication127.0 (71.0 to 483.0)
SecondaryPercentage of Subjects in Whom a Reduction in the Dose of Concomitant ITP Therapy Can be Achieved While Maintaining an Adequate Platelet Count

The percentage of subjects in whom a reduction in the dose of concomitant ITP therapy could be achieved while maintaining an adequate platelet count, the reduction event was clarified to apply only to reductions in the dose of concomitant ITP therapy occurring within a period of platelet response and the reduction event was not be prompted by an adverse event.

Time frame:
Up to 12 months

No measurements were reported for this outcome.

Adverse events

Collected over Baseline up to 62 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fostamatinib Disodium4/123 (3.3%)34/123 (27.6%)98/123 (79.7%)
Most frequent serious events
Showing 10 of 42
Most frequent serious events
EventFostamatinib Disodium
ThrombocytopeniaBlood and lymphatic system disorders8/123
EpistaxisRespiratory, thoracic and mediastinal disorders3/123
Transaminases increasedInvestigations2/123
Gastrointestinal haemorrhageGastrointestinal disorders2/123
SepsisInfections and infestations2/123
Aortic stenosisVascular disorders1/123
Chest painGeneral disorders1/123
Mucosal haemorrhageGeneral disorders1/123
PyrexiaGeneral disorders1/123
MenorrhagiaReproductive system and breast disorders1/123
Most frequent other events
Showing 10 of 19
Most frequent other events
EventFostamatinib Disodium
DiarrhoeaGastrointestinal disorders36/123
HypertensionVascular disorders22/123
EpistaxisRespiratory, thoracic and mediastinal disorders19/123
PetechiaeSkin and subcutaneous tissue disorders19/123
HeadacheNervous system disorders15/123
Upper respiratory tract infectionInfections and infestations14/123
DizzinessNervous system disorders13/123
ContusionInjury, poisoning and procedural complications12/123
VomitingGastrointestinal disorders11/123
NauseaGastrointestinal disorders11/123

Baseline characteristics

Baseline characteristics are analyzed with treated population data analysis set which was defined as all enrolled and treated subjects.

Age, Continuous
Age, Continuous(years)Overall Study
Median52.0 (20 to 88)
Sex: Female, Male
Sex: Female, Male(Participants)Overall Study
Female74
Male49
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Overall Study
Hispanic or Latino2
Not Hispanic or Latino121
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Overall Study
American Indian or Alaska Native0
Asian4
Native Hawaiian or Other Pacific Islander0
Black or African American4
White113
More than one race0
Unknown or Not Reported2
Region of Enrollment
Region of Enrollment(Participants)Overall Study
Romania1
Hungary2
United States17
Czechia10
United Kingdom18
Spain4
Canada4
Austria1
Netherlands1
Norway2
Poland34
Denmark1
Italy6
Bulgaria12
Australia10
08

Study locations

55 sites
  • Arizona Oncology Associates
    Tucson, Arizona 85710, United States
  • Bleeding & Clotting Disorders Institute
    Peoria, Illinois 61615, United States
  • Horizon Oncology Research, Inc
    Lafayette, Indiana 47905, United States
  • Center for Cancer and Blood Disorders
    Bethesda, Maryland 20817, United States
  • Weill Cornell Medical College/New York Presbyterian Hospital
    New York, New York 10065, United States
  • Weill Cornell Medicine
    New York, New York 10065, United States
  • East Carolina University, Brody School of Medicine
    Greenville, North Carolina 27834, United States
  • W.G. "Bill" Hefner VA Medical Center
    Salisbury, North Carolina 28144, United States
  • Signal Point Clinical Research Center LLC
    Middletown, Ohio 45042, United States
  • Concord Repatriation General Hospital
    Concord, New South Wales 2139, Australia
  • Liverpool Hospital
    Liverpool, New South Wales 2170, Australia
  • Prince of Wales Hospital
    Randwick, New South Wales 2031, Australia
  • Westmead Hospital
    Westmead, New South Wales 2145, Australia
  • Launceston General Hospital
    Launceston, Tasmania 7250, Australia
  • The Alfred
    Melbourne, Victoria 3004, Australia
  • Perth Blood Institute
    Nedlands, Western Australia 6009, Australia
  • Hanusch-Krankenhaus Wiener Gebietskrankenkasse
    Vienna, 1140, Austria
  • Specialized Hospital for Active Treatment of Hematology Diseases, EAD, Sofia, Department of Chemotherapy, Hemotherapy and Blood Inherited Diseases to Clinic of Clinical Hematology;
    Sofia, BG 1756, Bulgaria
  • UMHAT Dr. Georgi Stranski, EAD, Pleven, Clinic of Hematology
    Pleven, 5800, Bulgaria
  • UMHAT Aleksandrovska, EAD
    Sofia, 1431, Bulgaria
  • MHAT Hristo Botev, AD, Vratsa, First Internal Department
    Vratsa, 3000, Bulgaria
  • Hamilton Health Sciences Corporation
    Hamilton, Ontario L8N 3Z5, Canada
  • St. Michael's Hospital
    Toronto, Ontario M5B1W8, Canada
  • Fakultni nemocnice Brno
    Brno, 625 00, Czechia
  • Fakultni nemocnice Ostrava
    Ostrava-Poruba, 708 52, Czechia
  • Herlev Hospital
    Herlev, DK 2730, Denmark
  • Pecsi Tudomanyegyetem Klinikai Kozpont, I. sz. Belgyogyaszati Klinika
    Pecs, H-7624, Hungary
  • Istituto di Ematologia "Lorenzo e Ariosto Seràgnoli"
    Bologna, BO 40138, Italy
  • Azienda Ospedaliero-Universitaria "Santa Maria della Misericordia" - Clinica Ematologica
    Udine, 33100, Italy
  • HAGA ziekenhuis
    Den Haag, NL 2545 CH, Netherlands
  • Haukeland universitetssykehus, Helse Bergen HF
    Bergen, 5021, Norway
  • Sykehuset Østfold Kalnes
    Grålum, 1714, Norway
  • Samodzielny Publiczny Szpital Kliniczny Nr 1 we Wrocrlaw
    Wroclaw, Dolnoslaski 50-367, Poland
  • Wojewodzki Szpital Specjalistyczny im. J. Korczaka
    Slupsk, PO 76-200, Poland
  • Lkinika Hematologii I Transplantologii Uniwersyteckie Centrum Kliniczne
    Gdansk, 80-952, Poland
  • SPZOZ Szpital Uniwersytecki w Krakowie Pracownia Separacji Krwinek i Bank Komórek Krwiotwórczych Klinika Hematologii
    Kraków, 31-501, Poland
  • Wojewódzki Szpital Specjalistyczny im. M. Kopernika w Łodzi
    Lodz, 93-510, Poland
  • Specjalistyczny Gabinet Lekarski
    Lublin, 20-601, Poland
  • Szpital Wojewodzki w Opolu
    Opole, 45-061, Poland
  • Instytut Hematologii I Transfuzjologii
    Warszawa, 02-776, Poland
  • Spitalul Clinic Colentina, Hematologie
    Bucuresti, 020125, Romania
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
  • Hospital Universitari i Politécnic La Fe de Valencia
    Valencia, 46026, Spain
  • Colchester General Hospital
    Colchester, Essex CO4 5JL, United Kingdom
  • Royal Victoria Infirmary
    Newcastle-upon-Tyne, UK NE1 4LP, United Kingdom
  • Kent & Canterbury Hospital
    Canterbury, CT1 3NG, United Kingdom
  • James Paget University Hospital
    Great Yarmouth, NR31 6LA, United Kingdom
  • St. James's Hospital
    Leeds, LS9 7TF, United Kingdom
  • Leicester Royal Infirmary
    Leicester, LE1 5WW, United Kingdom
  • Royal Liverpool University Hospital
    Liverpool, L78XP, United Kingdom
  • Imperial College Healthcare NHS Trust
    London, W12 0HS, United Kingdom
  • University College Hospital
    London, WC1E 6AG, United Kingdom
  • Cancer and Haematology Centre
    Oxford, OX3 7LE, United Kingdom
  • University Hospital of North Midlands NHS Trust, Royal Stoke University Hospital
    Stoke-on-Trent, ST4 6QG, United Kingdom
09

References and documents

Publications

  • Cooper N, Altomare I, Thomas MR, Nicolson PLR, Watson SP, Markovtsov V, Todd LK, Masuda E, Bussel JB. Assessment of thrombotic risk during long-term treatment of immune thrombocytopenia with fostamatinib. Ther Adv Hematol. 2021 Apr 30;12:20406207211010875. doi: 10.1177/20406207211010875. eCollection 2021. PubMed 33995988 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2014, a primary completion of Jun 2020 and a completion of Jun 2020. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2023, 3 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2014
First posted
Mar 4, 2014
Start
Oct 2014
Primary completionActual
Jun 2, 2020
CompletionActual
Jun 2, 2020
Results first posted
Dec 11, 2023
Last update
Dec 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02077192
Responsible party
Sponsor
First posted
Mar 4, 2014
Start date
Oct 2014
Primary completion
Jun 2, 2020
Completion
Jun 2, 2020
Results posted
Dec 11, 2023
Last update
Dec 11, 2023

Study contacts

Rigel Pharmaceuticals, Inc.
study director · Rigel Pharmaceuticals,Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fostamatinib

Start the discussion